View ValuationAvia Avian 향후 성장Future 기준 점검 1/6Avia Avian (는) 각각 연간 5.9% 및 6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 4.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 19% 로 예상됩니다.핵심 정보5.9%이익 성장률4.53%EPS 성장률Chemicals 이익 성장43.6%매출 성장률6.0%향후 자기자본이익률18.95%애널리스트 커버리지Low마지막 업데이트19 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesBoard Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. No independent directors (5 non-independent directors). Director of Research, Development & Innovation and Director Angelica Jozar was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • Mar 12PT Avia Avian Tbk, Annual General Meeting, Apr 09, 2026PT Avia Avian Tbk, Annual General Meeting, Apr 09, 2026.공시 • Mar 03PT Avia Avian Tbk, Annual General Meeting, Apr 10, 2025PT Avia Avian Tbk, Annual General Meeting, Apr 10, 2025, at 09:30 FLE Standard Time.New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (101% cash payout ratio). Share price has been volatile over the past 3 months (7.8% average weekly change).Reported Earnings • Nov 05Third quarter 2024 earnings released: EPS: Rp5.81 (vs Rp5.39 in 3Q 2023)Third quarter 2024 results: EPS: Rp5.81 (up from Rp5.39 in 3Q 2023). Revenue: Rp1.78t (up 7.8% from 3Q 2023). Net income: Rp352.2b (up 5.5% from 3Q 2023). Profit margin: 20% (in line with 3Q 2023). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany.Buy Or Sell Opportunity • Sep 06Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to €0.026. The fair value is estimated to be €0.033, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last year. Earnings per share has grown by 15%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 17% in the next 2 years.Buy Or Sell Opportunity • Aug 04Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 12% to €0.025. The fair value is estimated to be €0.032, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last year. Earnings per share has grown by 15%. Revenue is forecast to grow by 19% in 2 years. Earnings are forecast to grow by 14% in the next 2 years.Reported Earnings • Aug 02Second quarter 2024 earnings released: EPS: Rp5.90 (vs Rp6.29 in 2Q 2023)Second quarter 2024 results: EPS: Rp5.90 (down from Rp6.29 in 2Q 2023). Revenue: Rp1.72t (flat on 2Q 2023). Net income: Rp362.0b (down 7.1% from 2Q 2023). Profit margin: 21% (down from 23% in 2Q 2023). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Chemicals industry in Germany.Reported Earnings • Apr 30First quarter 2024 earnings released: EPS: Rp7.24 (vs Rp6.73 in 1Q 2023)First quarter 2024 results: EPS: Rp7.24 (up from Rp6.73 in 1Q 2023). Revenue: Rp1.91t (up 6.9% from 1Q 2023). Net income: Rp446.2b (up 7.1% from 1Q 2023). Profit margin: 23% (in line with 1Q 2023). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany.Upcoming Dividend • Apr 16Upcoming dividend of Rp11.00 per shareEligible shareholders must have bought the stock before 23 April 2024. Payment date: 30 April 2024. Payout ratio is on the higher end at 93%, and the cash payout ratio is above 100%. Trailing yield: 4.0%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (4.8%).Board Change • Apr 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Rachman Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 29Full year 2023 earnings released: EPS: Rp26.51 (vs Rp22.61 in FY 2022)Full year 2023 results: EPS: Rp26.51 (up from Rp22.61 in FY 2022). Revenue: Rp7.02t (up 4.8% from FY 2022). Net income: Rp1.64t (up 17% from FY 2022). Profit margin: 23% (up from 21% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.9% p.a. on average during the next 2 years, compared to a 3.2% growth forecast for the Chemicals industry in Germany.New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (93% payout ratio). Share price has been volatile over the past 3 months (7.1% average weekly change).Buy Or Sell Opportunity • Jan 24Now 24% overvalued after recent price riseOver the last 90 days, the stock has risen 14% to €0.033. The fair value is estimated to be €0.026, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 20% in 2 years. Earnings are forecast to grow by 25% in the next 2 years.Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: Rp5.39 (vs Rp4.89 in 3Q 2022)Third quarter 2023 results: EPS: Rp5.39 (up from Rp4.89 in 3Q 2022). Revenue: Rp1.66t (up 4.9% from 3Q 2022). Net income: Rp333.7b (up 10% from 3Q 2022). Profit margin: 20% (up from 19% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany.Upcoming Dividend • Oct 18Upcoming dividend of Rp11.00 per share at 4.2% yieldEligible shareholders must have bought the stock before 24 October 2023. Payment date: 31 October 2023. Payout ratio is a comfortable 48% and this is well supported by cash flows. Trailing yield: 4.2%. Lower than top quartile of German dividend payers (5.0%). Lower than average of industry peers (6.3%).Board Change • Sep 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Rachman Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Sep 01No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Rachman Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 03Second quarter 2023 earnings released: EPS: Rp6.29 (vs Rp6.32 in 2Q 2022)Second quarter 2023 results: EPS: Rp6.29 (down from Rp6.32 in 2Q 2022). Revenue: Rp1.73t (flat on 2Q 2022). Net income: Rp389.9b (flat on 2Q 2022). Profit margin: 23% (in line with 2Q 2022). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany.Board Change • May 11No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Rachman Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Apr 25Upcoming dividend of Rp11.00 per share at 3.9% yieldEligible shareholders must have bought the stock before 02 May 2023. Payment date: 09 May 2023. Payout ratio and cash payout ratio are on the higher end at 93% and 87% respectively. Trailing yield: 3.9%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (5.4%).Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Noor Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 04Second quarter 2022 earnings releasedSecond quarter 2022 results: EPS: Rp6.32. Revenue: Rp1.74t (flat on 2Q 2021). Net income: Rp391.7b (up Rp391.7b from 2Q 2021). Profit margin: 23% (up from null in 2Q 2021). Over the next year, revenue is forecast to grow 19%, compared to a 3.7% growth forecast for the industry in Germany.Board Change • Aug 02No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Independent Commissioner Mohammad Noor Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.이익 및 매출 성장 예측DB:P2C - 애널리스트 향후 추정치 및 과거 재무 데이터 (IDR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20289,940,3252,046,6191,899,3502,230,800412/31/20279,264,0561,922,7741,635,6502,054,167412/31/20268,705,8261,768,9211,378,3001,937,45043/31/20268,462,9681,803,5461,552,2662,011,082N/A12/31/20258,123,6851,747,4621,275,0081,738,165N/A9/30/20257,994,3741,693,7111,140,2101,712,841N/A6/30/20257,735,1151,638,6271,108,8481,614,350N/A3/31/20257,584,9331,665,1491,292,8811,782,947N/A12/31/20247,471,3561,664,3411,317,0461,766,128N/A9/30/20247,257,8761,662,2951,390,5181,730,372N/A6/30/20247,129,4561,643,7961,150,6321,461,701N/A3/31/20247,140,3081,671,6471,400,9071,673,343N/A12/31/20237,016,8821,642,1661,385,9861,640,834N/A9/30/20236,899,9221,460,5721,597,2741,807,331N/A6/30/20236,822,7801,430,0691,751,5301,945,160N/A3/31/20236,836,7361,431,8851,454,5831,632,657N/A12/31/20226,694,1711,400,5611,276,9061,461,499N/A9/30/20226,760,5871,455,9981,139,3891,321,814N/A6/30/20226,925,3521,490,8731,015,4871,181,247N/A3/31/20226,618,0551,365,193923,7281,082,994N/A12/31/20216,779,6431,434,6131,133,5141,271,999N/A12/31/20205,731,2611,136,1471,682,7931,802,054N/A12/31/20195,669,732959,368N/A946,584N/A12/31/20185,122,1721,038,022N/A736,066N/A12/31/20174,311,557801,143N/A751,249N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: P2C 의 연간 예상 수익 증가율(5.9%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: P2C 의 연간 수익(5.9%)이 German 시장(17.2%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: P2C 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: P2C 의 수익(연간 6%)이 German 시장(연간 6.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: P2C 의 수익(연간 6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: P2C의 자본 수익률은 3년 후 19%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/30 21:30종가2026/05/18 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PT Avia Avian Tbk는 8명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Nashrullah Putra SulaemanDBS Bank LtdKevin HalimMaybank Research Pte. Ltd.null nullMaybank Research Pte. Ltd.5명의 분석가 더 보기
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. No independent directors (5 non-independent directors). Director of Research, Development & Innovation and Director Angelica Jozar was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • Mar 12PT Avia Avian Tbk, Annual General Meeting, Apr 09, 2026PT Avia Avian Tbk, Annual General Meeting, Apr 09, 2026.
공시 • Mar 03PT Avia Avian Tbk, Annual General Meeting, Apr 10, 2025PT Avia Avian Tbk, Annual General Meeting, Apr 10, 2025, at 09:30 FLE Standard Time.
New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (101% cash payout ratio). Share price has been volatile over the past 3 months (7.8% average weekly change).
Reported Earnings • Nov 05Third quarter 2024 earnings released: EPS: Rp5.81 (vs Rp5.39 in 3Q 2023)Third quarter 2024 results: EPS: Rp5.81 (up from Rp5.39 in 3Q 2023). Revenue: Rp1.78t (up 7.8% from 3Q 2023). Net income: Rp352.2b (up 5.5% from 3Q 2023). Profit margin: 20% (in line with 3Q 2023). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany.
Buy Or Sell Opportunity • Sep 06Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to €0.026. The fair value is estimated to be €0.033, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last year. Earnings per share has grown by 15%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 17% in the next 2 years.
Buy Or Sell Opportunity • Aug 04Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 12% to €0.025. The fair value is estimated to be €0.032, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last year. Earnings per share has grown by 15%. Revenue is forecast to grow by 19% in 2 years. Earnings are forecast to grow by 14% in the next 2 years.
Reported Earnings • Aug 02Second quarter 2024 earnings released: EPS: Rp5.90 (vs Rp6.29 in 2Q 2023)Second quarter 2024 results: EPS: Rp5.90 (down from Rp6.29 in 2Q 2023). Revenue: Rp1.72t (flat on 2Q 2023). Net income: Rp362.0b (down 7.1% from 2Q 2023). Profit margin: 21% (down from 23% in 2Q 2023). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Chemicals industry in Germany.
Reported Earnings • Apr 30First quarter 2024 earnings released: EPS: Rp7.24 (vs Rp6.73 in 1Q 2023)First quarter 2024 results: EPS: Rp7.24 (up from Rp6.73 in 1Q 2023). Revenue: Rp1.91t (up 6.9% from 1Q 2023). Net income: Rp446.2b (up 7.1% from 1Q 2023). Profit margin: 23% (in line with 1Q 2023). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany.
Upcoming Dividend • Apr 16Upcoming dividend of Rp11.00 per shareEligible shareholders must have bought the stock before 23 April 2024. Payment date: 30 April 2024. Payout ratio is on the higher end at 93%, and the cash payout ratio is above 100%. Trailing yield: 4.0%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (4.8%).
Board Change • Apr 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Rachman Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 29Full year 2023 earnings released: EPS: Rp26.51 (vs Rp22.61 in FY 2022)Full year 2023 results: EPS: Rp26.51 (up from Rp22.61 in FY 2022). Revenue: Rp7.02t (up 4.8% from FY 2022). Net income: Rp1.64t (up 17% from FY 2022). Profit margin: 23% (up from 21% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.9% p.a. on average during the next 2 years, compared to a 3.2% growth forecast for the Chemicals industry in Germany.
New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (93% payout ratio). Share price has been volatile over the past 3 months (7.1% average weekly change).
Buy Or Sell Opportunity • Jan 24Now 24% overvalued after recent price riseOver the last 90 days, the stock has risen 14% to €0.033. The fair value is estimated to be €0.026, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 20% in 2 years. Earnings are forecast to grow by 25% in the next 2 years.
Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: Rp5.39 (vs Rp4.89 in 3Q 2022)Third quarter 2023 results: EPS: Rp5.39 (up from Rp4.89 in 3Q 2022). Revenue: Rp1.66t (up 4.9% from 3Q 2022). Net income: Rp333.7b (up 10% from 3Q 2022). Profit margin: 20% (up from 19% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany.
Upcoming Dividend • Oct 18Upcoming dividend of Rp11.00 per share at 4.2% yieldEligible shareholders must have bought the stock before 24 October 2023. Payment date: 31 October 2023. Payout ratio is a comfortable 48% and this is well supported by cash flows. Trailing yield: 4.2%. Lower than top quartile of German dividend payers (5.0%). Lower than average of industry peers (6.3%).
Board Change • Sep 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Rachman Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Sep 01No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Rachman Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 03Second quarter 2023 earnings released: EPS: Rp6.29 (vs Rp6.32 in 2Q 2022)Second quarter 2023 results: EPS: Rp6.29 (down from Rp6.32 in 2Q 2022). Revenue: Rp1.73t (flat on 2Q 2022). Net income: Rp389.9b (flat on 2Q 2022). Profit margin: 23% (in line with 2Q 2022). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany.
Board Change • May 11No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Rachman Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Apr 25Upcoming dividend of Rp11.00 per share at 3.9% yieldEligible shareholders must have bought the stock before 02 May 2023. Payment date: 09 May 2023. Payout ratio and cash payout ratio are on the higher end at 93% and 87% respectively. Trailing yield: 3.9%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (5.4%).
Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Mohammad Noor Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 04Second quarter 2022 earnings releasedSecond quarter 2022 results: EPS: Rp6.32. Revenue: Rp1.74t (flat on 2Q 2021). Net income: Rp391.7b (up Rp391.7b from 2Q 2021). Profit margin: 23% (up from null in 2Q 2021). Over the next year, revenue is forecast to grow 19%, compared to a 3.7% growth forecast for the industry in Germany.
Board Change • Aug 02No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Independent Commissioner Mohammad Noor Soejoeti was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.